State Street’s Plus Therapeutics PSTV Stock Holding History

State Street’s Portfolio PSTV Stock Details PSTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76.2K	Hold	18,756	–	–	﹤0.01%	4073
2025 Q4	$240K	Buy	18,756 +5,080	+37%	+$76.6K	﹤0.01%	3861
2025 Q3	$234K	Buy	+13,676	New	+$168K	﹤0.01%	3868
2023 Q2	–	Sell	-92	Closed	-$9.98K	–	4717
2023 Q1	$9.98K	Hold	92	–	–	﹤0.01%	4742
2022 Q4	$10.9K	Hold	92	–	–	﹤0.01%	4798
2022 Q3	$15K	Hold	92	–	–	﹤0.01%	4860
2022 Q2	$19K	Hold	92	–	–	﹤0.01%	4879
2022 Q1	$34K	Hold	92	–	–	﹤0.01%	4853
2021 Q4	$36K	Hold	92	–	–	﹤0.01%	4745
2021 Q3	$66K	Buy	92 +1	+1%	+$763	﹤0.01%	4619
2021 Q2	$88K	Buy	+91	New	+$82.2K	﹤0.01%	4385
2016 Q2	–	Hold	0	–	-$7K	–	3757
2016 Q1	–	Hold	0	–	–	–	3711
2015 Q4	–	Hold	0	–	–	–	3707
2015 Q3	–	Hold	0	–	–	–	3689
2015 Q2	–	Hold	0	–	–	–	3683
2015 Q1	–	Hold	0	–	–	–	3211
2014 Q4	–	Hold	0	–	–	–	3408
2014 Q3	–	Hold	0	–	–	–	3353
2014 Q2	–	Hold	0	–	–	–	3039
2014 Q1	–	Hold	0	–	–	–	2978
2013 Q4	–	Hold	0	–	–	–	3023
2013 Q3	–	Hold	0	–	–	–	3045
2013 Q2	–	Hold	0	–	–	–	2995

Other funds holding PSTV

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street's PSTV Position: Q1 2026 in Review

State Street held its Plus Therapeutics (PSTV) position steady in Q1 2026 at 18,756 shares worth $76.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4073.

State Street first reported a position in PSTV in Q2 2021 and has held it in 11 quarters since. The position peaked at $240K in Q4 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

State Street held 18,756 shares of Plus Therapeutics worth $76.2K as of Q1 2026.
State Street left its Plus Therapeutics share count unchanged in Q1 2026.
Plus Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4073 holding.
State Street first reported a position in Plus Therapeutics in Q2 2021 and has held it in 11 quarters since.
State Street's Plus Therapeutics position peaked at $240K in Q4 2025.
23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.